Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.59B, -1.5% YoY · Filed Aug 5, 2026
The Chemours Company (CC) files with the SEC under industry code 2800, Chemicals & Allied Products. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.6 billion and a net loss of $274.0 million. Free cash flow was $114.0 million. As of Jun 30, 2026 it held $671.0 million in cash and investments and $4.1 billion in total debt.
Revenue
$1.59B
-1.5% vs year-ago quarter
Net income
$-274.00M
+27.9% vs year-ago quarter
Operating cash flow
$158.00M
+69.9% vs year-ago quarter
Free cash flow
$114.00M
+128.0% vs year-ago quarter
EPS
$-1.81
+28.5% vs year-ago quarter
Dividend per share
$0.09
+0.0% vs year-ago quarter
Shares outstanding
150.50M
+0.5% vs year-ago quarter
Net cash
$-3.46B
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Chemicals & Allied Products (SIC 2800)
- Listed as
- CC (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1627223
- Former names
- Chemours Company, LLC (until Apr 21, 2015)
Other Chemicals & Allied Products companies
- Akzo Nobel NV AKZOY
- Solstice Advanced Materials Inc. SOLS
- Balchem Corp BCPC
- Perimeter Solutions, Inc. PRM
- Ingevity Corp NGVT
- Innospec Inc. IOSP
- OLIN Corp OLN
- Huntsman CORP HUN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.6B | $1.4B | $1.3B | $1.5B | $1.6B |
| Net income | -$274.0M | -$29.0M | -$47.0M | $46.0M | -$380.0M |
| Diluted EPS | -$1.81 | -$0.19 | -$0.31 | $0.31 | -$2.53 |
| Operating cash flow | $158.0M | -$44.0M | $137.0M | $146.0M | $93.0M |
| Free cash flow | $114.0M | -$93.0M | $92.0M | $105.0M | $50.0M |
| Total assets | $7.2B | $7.3B | $7.4B | $7.5B | $7.5B |
| Total liabilities | $7.2B | $7.1B | $7.1B | $7.3B | $7.2B |
| Stockholders' equity | -$49.0M | $215.0M | $250.0M | $274.0M | $228.0M |
| Cash and investments | $671.0M | $563.0M | $670.0M | $613.0M | $502.0M |
| Total debt | $4.1B | $4.4B | $4.4B | $4.4B | $4.4B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K/A | Amended annual report | Nov 3, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 10, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
All 1000 The Chemours Company SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.